Latest From Inhibrx Inc.
CF-focused Vertex will buy Exonics and expand a collaboration with CRISPR Therapeutics, with plans to develop therapies for DMD and myotonic dystrophy type 1. Merck acquires TGFβ-focused Tilos, while Achaogen offloads most of its assets at auction.
AgomAb, CinCor and Confo Therapeutics secure Series A financing, while AlloVir closes a $121m Series B and more venture financing in April and May.
The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.
Private Company Edition: Venture capital for emerging therapeutics companies in the US and in ex-US regions reached all-time highs in 2018. Also, Alphamab raises $60m Series B, three new VC funds launch and FLX changes its name to RAPT.
- Drug Discovery Tools
- Therapeutic Areas
- Infectious & Viral Diseases
- Respiratory, Pulmonary
- Inhibrx LLC
- North America
- Parent & Subsidiaries
- Inhibrx Inc.
- Senior Management
Mark Lappe, CEO
Brendan Eckelman, PhD, CSO & EVP, Corp. Strategy
- Contact Info
Phone: (858) 759-1499
11025 North Torrey Pines Rd., Ste. 200
La Jolla, CA 92037
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.